Cover Image
市場調查報告書

止血及組織密封劑市場分析:各產品 (局部止血,積極性,機械性,流體止血,黏劑,組織密封膠,合成/天然組織密封膠,黏合阻隔產品) 、及至2022年的市場區隔預測

Hemostasis And Tissue Sealing Agents Market Analysis By Product (Topical Hemostats, Active, Mechanical, Flowable Hemostats, Adhesives, Tissue Sealants, Synthetic/Natural Tissue Sealant, Adhesion Barrier Products) And Segment Forecasts To 2022

出版商 Grand View Research, Inc. 商品編碼 355228
出版日期 內容資訊 英文 83 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
止血及組織密封劑市場分析:各產品 (局部止血,積極性,機械性,流體止血,黏劑,組織密封膠,合成/天然組織密封膠,黏合阻隔產品) 、及至2022年的市場區隔預測 Hemostasis And Tissue Sealing Agents Market Analysis By Product (Topical Hemostats, Active, Mechanical, Flowable Hemostats, Adhesives, Tissue Sealants, Synthetic/Natural Tissue Sealant, Adhesion Barrier Products) And Segment Forecasts To 2022
出版日期: 2015年11月03日 內容資訊: 英文 83 Pages
簡介

全球止血及組織密封劑市場,預計至2022年達到74億美元。止血及組織密封劑,由其失血防止能力而普及,微創技術迅速的尋求發展和早期復甦的患者的增加,促進市場成長。

本報告提供全球止血及組織密封劑市場現狀與至2022年的成長預測,各產品及各地區趨勢,及主要企業的簡介等彙整。

第1章 調查方法與調查範圍

第2章 摘要整理

第3章 產業預測

  • 市場區隔
  • 市場規模與成長預測
  • 市場趨勢
    • 促進要素
    • 阻礙要素
  • 市場機會
  • 產業分析:波特
  • 企業市場佔有率
  • PESTEL分析

第4章 各產品市場預測

  • 各產品收益佔有率
  • 局部止血市場
    • 主動
    • 機械性
    • 流動性
  • 黏劑及組織密封膠市場
    • 合成
    • 天然
    • 阻隔產品

第5章 各地區預測

  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第6章 競爭環境

  • Johnson & Johnson
  • CryoLife Inc.
  • Advance Medical Solution (AMS) Group Plc.
  • Cohera Medical Inc.
  • Integra Life Sciences Corporation
  • Pfizer Inc.
  • C R Bard Inc.
  • Cohesion Technologies Inc
  • HyperBranch Medical Technology
  • Biomet Inc.
  • Covidien Plc
  • B Braun Medical Inc.
  • Smith & Nephew

圖表

目錄
Product Code: 978-1-68038-597-7

The global hemostasis and tissue sealing agents market is expected to reach USD 7.4 billion by 2022, according to a new report by Grand View Research Inc. The global hemostasis and tissue sealing agents market has gained popularity over time due to its ability in preventing blood loss. Rapid growth of minimal invasive technology and rising demand for faster recovery by patients is expected to promote market growth over the forecast period.

According to the CDC, approximately 150 million of American population is currently suffering with at least one chronic condition, which leads to surgeries and even mortality at times. An estimate over the rising incidence was made by the CDC, which concluded that over 48% of the entire American population is expected to suffer by chronic condition.

The demand for wound management is expected to rise with increasing chronic disease incidence over the next seven years. The Public Health Agency of Canada in its report stated that the chronic disease occurrence rate is anticipated to increase by 14% annually and four out of five cases are of high risk requiring immediate treatment and surgeries.

Further key findings from the report suggest:

The hemostats market is expected to grow at a CAGR of over9.0% over the forecast period owing to, the rise in global volume of surgeries and increased applicability across a variety of surgeries. The products avoid occurrence of hypovolemic shock, thrombocytopenia, blood transfusions, and increase in post-operative complications.

Flowable hemostats are a combination of active and mechanical agents. They function by blocking blood flow and also convert fibrinogen into fibrin for the coagulation process to commence. This segment is expected to grow at a lucrative CAGR of over 10.0% from 2015 to 2022.

North America is estimated to be the largest market for the hemostasis and tissue sealing agents over the forecast period and is expected to account for over 30.0% share by 2022.

Asia Pacific is identified as a lucrative market due to a rapid growth in the surgery volume brought about by the introduction of medical tourism. It is anticipated to account for over 27.0% of the overall market share by 2022. The Europe hemostasis and tissue sealing agents market is expected to be driven by the rise in geriatric population base, which is expected to ultimately lead to a surge in procedure volume.

Some key players of this market include Johnson & Johnson, CryoLife Inc, Pfizer, C R Bard, B Braun, Covidien, and Smith & Nephew.

Market participants are involved in technological advancements in order to ensure sustainability and improve regional presence.

For instance, in March 2015, Ethicon announced higher efficiency of EVARREST fibrin sealant patch as compared to its substitute, TachoSil patch (Baxter). Further study would be conducted at the St. Vincent Heart Centre of Indiana to understand added advantages that the product can offer.

In August 2015, Integra Life Sciences announced a new application of the Integra Dermal Regeneration Template in chronic diabetes-based foot ulcers. The product is expected to be used for treating these ulcers post its approval by the FDA in 2016.

Table of Content

Chapter 1. Methodology and Scope

  • 1.1. Research methodology
  • 1.2. Research scope & assumption
  • 1.3. List of data sources

Chapter 2. Executive Summary

  • 2.1. Hemostasis and tissue sealing agents - Industry Summary and Key Buying Criteria, 2012 - 2022

Chapter 3. Hemostasis and tissue sealing agents Industry Outlook

  • 3.1. Hemostasis and tissue sealing agents market segmentation
  • 3.2. Hemostasis and tissue sealing agents market size and growth prospects, 2012-2022
  • 3.3. Hemostasis and tissue sealing agents market dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Key opportunities prioritized
  • 3.5. Industry analysis - Porter's
  • 3.6. Hemostasis and tissue sealing agents : Company market share, 2014
  • 3.7. Hemostasis and tissue sealing agents market PESTEL analysis, 2014

Chapter 4. Hemostasis and tissue sealing agents Product Outlook

  • 4.1. Hemostasis and tissue sealing agents market share by product, 2014 & 2022
  • 4.2. Topical hemostats market estimates and forecasts, 2012 - 2022 (USD Million)
    • 4.2.1. Active market estimates and forecasts, 2012 - 2022 (USD Million)
    • 4.2.2. Mechanical market estimates and forecasts, 2012 - 2022 (USD Million)
    • 4.2.3. Flowable market estimates and forecasts, 2012 - 2022 (USD Million)
  • 4.3. Adhesive & tissue sealant market estimates and forecasts, 2012 - 2022 (USD Million)
    • 4.3.1. Synthetic tissue sealant market estimates and forecasts, 2012 - 2022 (USD Million)
    • 4.3.2. Natural tissue sealant market estimates and forecasts, 2012 - 2022 (USD Million)
    • 4.3.3. Adhesion barrier products market estimates and forecasts, 2012 - 2022 (USD Million)

Chapter 5. Hemostasis and tissue sealing agents Regional Outlook

  • 5.1. North America
    • 5.1.1. North America market, by product, 2012 - 2022 (USD Million)
      • 5.1.1.1. U.S. market estimates and forecasts
      • 5.1.1.2. Canada market estimates and forecasts
  • 5.2. Europe
    • 5.2.1. Europe market, by product, 2012 - 2022 (USD Million)
      • 5.2.1.1. UK market estimates and forecasts
      • 5.2.1.2. Germany market estimates and forecasts
      • 5.2.1.3. France market estimates and forecasts
      • 5.2.1.4. Italy market estimates and forecasts
      • 5.2.1.5. Spain market estimates and forecasts
  • 5.3. Asia Pacific
    • 5.3.1. Asia Pacific market, by product, 2012 - 2022 (USD Million)
      • 5.3.1.1. Japan market estimates and forecasts
      • 5.3.1.2. China market estimates and forecasts
      • 5.3.1.3. India market estimates and forecasts
  • 5.4. Latin America
    • 5.4.1. Latin America market, by product, 2012 - 2022 (USD Million)
      • 5.4.1.1. Brazil market estimates and forecasts
  • 5.5. MEA
    • 5.5.1. MEA market, by product, 2012 - 2022 (USD Million)
      • 5.5.1.1. South Africa market estimates and forecasts

Chapter 6. Competitive Landscape

  • 6.1. Johnson & Johnson
    • 6.1.1. Company Overview
    • 6.1.2. Financial Performance
    • 6.1.3. Product Benchmarking
    • 6.1.4. Strategic Initiatives
  • 6.2. CryoLife Inc.
    • 6.2.1. Company Overview
    • 6.2.2. Financial Performance
    • 6.2.3. Product Benchmarking
    • 6.2.4. Strategic Initiatives
  • 6.3. Advance Medical Solution (AMS) Group Plc.
    • 6.3.1. Company Overview
    • 6.3.2. Financial Performance
    • 6.3.3. Product Benchmarking
    • 6.3.4. Strategic Initiatives
  • 6.4. Cohera Medical Inc.
    • 6.4.1. Company Overview
    • 6.4.2. Financial Performance
    • 6.4.3. Product Benchmarking
    • 6.4.4. Strategic Initiatives
  • 6.5. Integra Life Sciences Corporation
    • 6.5.1. Company Overview
    • 6.5.2. Financial Performance
    • 6.5.3. Product Benchmarking
    • 6.5.4. Strategic Initiatives
  • 6.6. Pfizer Inc.
    • 6.6.1. Company Overview
    • 6.6.2. Financial Performance
    • 6.6.3. Product Benchmarking
    • 6.6.4. Strategic Initiatives
  • 6.7. C R Bard Inc.
    • 6.7.1. Company Overview
    • 6.7.2. Financial Performance
    • 6.7.3. Product Benchmarking
    • 6.7.4. Strategic Initiatives
  • 6.8. Cohesion Technologies Inc
    • 6.8.1. Company Overview
    • 6.8.2. Financial Performance
    • 6.8.3. Product Benchmarking
    • 6.8.4. Strategic Initiatives
  • 6.9. HyperBranch Medical Technology
    • 6.9.1. Company Overview
    • 6.9.2. Financial Performance
    • 6.9.3. Product Benchmarking
    • 6.9.4. Strategic Initiatives
  • 6.10. Biomet Inc.
    • 6.10.1. Company Overview
    • 6.10.2. Financial Performance
    • 6.10.3. Product Benchmarking
    • 6.10.4. Strategic Initiatives
  • 6.11. Covidien Plc
    • 6.11.1. Company Overview
    • 6.11.2. Financial Performance
    • 6.11.3. Product Benchmarking
    • 6.11.4. Strategic Initiatives
  • 6.12. B Braun Medical Inc.
    • 6.12.1. Company Overview
    • 6.12.2. Financial Performance
    • 6.12.3. Product Benchmarking
    • 6.12.4. Strategic Initiatives
  • 6.13. Smith & Nephew
    • 6.13.1. Company Overview
    • 6.13.2. Financial Performance
    • 6.13.3. Product Benchmarking
    • 6.13.4. Strategic Initiatives

List of Tables

  • 1. Hemostasis and tissue sealing agents - Industry Snapshot
  • 2. Hemostasis and tissue sealing agents market , by product, 2012 - 2022 (USD million)
  • 3. Hemostasis and tissue sealing agents market , by region, 2012 - 2022 (USD million)
  • 4. Hemostasis and tissue sealing agents market - Key market drivers analysis
  • 5. Hemostasis and tissue sealing agents market - Key market restraints analysis
  • 6. North America hemostasis and tissue sealing agents market , by product, 2012 - 2022 (USD million)
  • 7. Europe hemostasis and tissue sealing agents market , by product, 2012 - 2022 (USD million)
  • 8. Asia Pacific hemostasis and tissue sealing agents market , by product, 2012 - 2022 (USD million)
  • 9. Latin America hemostasis and tissue sealing agents market , by product, 2012 - 2022 (USD million)
  • 10. MEA hemostasis and tissue sealing agents market , by product, 2012 - 2022 (USD million)

List of Figures

  • 1. Hemostasis and tissue sealing agents market segmentation
  • 2. Global Hemostasis and tissue sealing agents market revenue, 2012 - 2022
  • 3. Hemostasis and tissue sealing agents market dynamics
  • 4. Key Opportunities Prioritized
  • 5. Hemostasis and tissue sealing agents market Analysis - Porter's
  • 6. Hemostasis and tissue sealing agents market Analysis - PESTEL Analysis
  • 7. Global Hemostasis and tissue sealing agents market , by product, 2012 - 2022 (USD million)
  • 8. Topical hemostats market, 2012 - 2022 (USD million)
  • 9. Active topical hemostats market, 2012 - 2022 (USD million)
  • 10. Mechanical topical hemostats market, 2012 - 2022 (USD million)
  • 11. Flowable topical hemostats market, 2012 - 2022 (USD million)
  • 12. Tissue sealants market, 2012 - 2022 (USD million)
  • 13. Natural tissue sealants market, 2012 - 2022 (USD million)
  • 14. Synthetic tissue sealants market, 2012 - 2022 (USD million)
  • 15. Adhesion barrier products market, 2012 - 2022 (USD million)
  • 16. Global hemostasis and tissue sealing agents market , by region 2012 to 2022 (USD million)
  • 17. North America market, by product, 2012 to 2022 (USD million)
  • 18. Europe market, by product, 2012 to 2022 (USD million)
  • 19. Asia Pacific market, by product, 2012 to 2022 (USD million)
  • 20. Latin America market, by product, 2012 to 2022 (USD million)
  • 21. MEA market, by product, 2012 to 2022 (USD million)
Back to Top